Independent Pharmacies Continue to Face Financial Hardships as the Clock Ticks on PBM Reform
As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.
Tocilizumab-aazg Is First IV, Subcutaneous Tocilizumab Biosimilar With FDA Approval
The biosimilar represents a comprehensive, accessible, and high-quality treatment option for patients in the US treated with tocilizumab.
HHS Says It’s Working to Help Those Impacted by Change Healthcare Cyberattack
The statement says the agency is talking with CMS to initiate new flexibilities, but multiple advocacy groups have said it’s not nearly enough.
Ozempic Lowers Risk of Kidney Disease Progression, Cardiovascular Events by 24%
Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.
Breaking: Benzene Found in Acne Products From Major Brands, Prompts FDA Recall Petition
Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.
Breaking: FDA Clears Dexcom Stelo, First OTC Continuous Glucose Monitor
Dexcom's Stelo will be available in summer 2024.
FDA Approves Interchangeable Denosumab Biosimilar
The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.
Government, Industry Leaders Address the Growing Issue of PBM Practices
Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.
FDA Approves Eye Drops to Treat Inflammation, Pain After Ocular Surgery
Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.
Dupilumab Safe, Effective for Atopic Dermatitis in Real-Life Settings
In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.
Small Doses: February 26 to March 1
Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.
Rx Roundup: Quiz of the Week
Test your pharmacy news knowledge with our weekly quiz: February 26 to March 1
Dual GLP-1/GIP Receptor Agonist Shows Positive Results in Phase 2 Study
Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.
PA Programs Draw Pharmacy’s Best and Brightest
Physician assistants have pulled well ahead of pharmacists in a recent listing of top jobs in the health care profession.
NCPA Pharmacy Ownership Workshop Empowers, Educates, and Inspires
Three times each year, the National Community Pharmacists Association holds intensive workshops that drill down into the nitty gritty of pharmacy ownership.
Understanding the Foundations of Pharmacy Financial Health
Pharmacy schools specialize in training students as experts in patient care—not as expert business owners.
OTC Product Roundup: Cough, Cold, and Flu
These OTC products are recommended to address a variety of symptoms that occur during cold and flu seasons.
Stealing With Our Eyes Open
How much longer can independent pharmacists survive with the current method of reimbursement?
Morning Rx: February 12, 2024
Your look at today’s health care headlines, including production challenges at a Aurobindo, Pfizer’s Super Bowl commercial, and Novo Nordisk’s semaglutide lawsuits.
HHS Issues Reminder to Health Plans: Provide Contraceptive Coverage
The Affordable Care Act mandates that contraceptives must be covered by health plans and insurers without cost-sharing.
City of Boston Sues Major PBMs Over Role in Opioid Crisis
The lawsuit claims several pharmacy benefit managers, including Express Scripts and OptumRx, collaborated with manufacturers in “deceptive” and “dangerous” marketing.
Plant Protein Intake Linked to Disease Prevention, Healthy Aging Among Women
Findings from the current study lend scientific credence to the idea that making informed dietary choices can help promote favorable health outcomes.
Florida Drug Importation Program Faces Nationwide Opposition From Pharmacy Organizations
Just weeks after it gained FDA approval, pharmacy organizations have come forward to voice concerns about the safety and security of Florida’s drug importation program.
FDA Grants Breakthrough Device Designation to Prescription Digital Therapeutic App for Schizophrenia
The CONVOKE study is investigating the effectiveness of the smartphone app as a therapy for negative symptoms of schizophrenia among adults.
Reduced Drug Use Could Help Patients With Stimulant Use Disorders Achieve Recovery
A recent study found that reduced drug use was associated with a decrease in cravings, drug seeking behaviors, and depression severity.
Understanding Prior Authorization to Ensure Timely Medication Access
According to Tyler Milliken, educating providers about prior authorization, along with other insurance processes and policies, plays a crucial role in advancing patients along their path to care.
How Co-Pay Accumulators, Maximizers Disrupt Patient Access to Care
In this conversation from the Healthcare Advocate Summit, Ned Woody, associate director of field reimbursement at Daiichi Sankyo Inc. - Oncology, discusses the disruptive impact that these programs have on patients.
Advocacy Key For Supporting Transgender Rights in Health Care Settings
Advocates can amplify the voices of transgender patients as they overcome barriers to health care, said Molly Crowther in a conversation at the 2023 Healthcare Advocate Summit.
FDA Approval Makes Florida First State to Import Drugs From Canada
By importing drugs in bulk from Canada, Florida aims to relieve the financial strain faced by patients who struggle to afford necessary medications.
Positive Results Announced From Phase 3 Trial of Oral Weekly Risperidone for Schizophrenia
The Starlyng-1 study showed that the treatment met its primary endpoint of a one-sided Cmin of >0.80; a one-sided Cmax of <1.25; and a two-sided Cavg of 0.80-1.40, with 90% confidence limits.
